Gilead is prioritizing registration in 18 countries that represent about 70% of the HIV burden in the countries named in the license. These countries were identified in consultation with external partners: Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Thailand, Uganda, Vietnam, Zambia and Zimbabwe. Gilead will prioritize providing lenacapavir until generic versions are available.